The combination of liraglutide, a GLP-1 receptor agonist, and SGAs has potential benefits on body weight and lipid metabolism in patients with schizophrenia, but patients must receive daily subcutaneous injections and have a relatively high rate of adverse events (Whicher et al., 2019). Here, GLP1R is linked to schizophrenia.